The global demand for regenerative therapies is reaching new heights, but researchers and patients alike continue to face major barriers as costs soar and production remains largely limited to small batches.
Cellcolabs, a Stockholm-based biotech founded in 2021 by CEO Dr Mattias Bernow and his team, is determined to change that. The company’s solution lies in industrial-scale production processes, designed to slash the cost of stem cells by 90 per cent over the coming decade and open access to treatments and breakthroughs worldwide.
Cellcolabs announced today that it has raised $12 million in a round led by Titian Capital. The fresh capital boosts the company’s total funding to $37 million and will help drive ongoing technical development as well as an ambitious international expansion.
Dr Mattias Bernow, CEO of Cellcolabs, comments: “The industry is reaching an inflexion point. Scientific evidence is mounting. Regulatory pathways are opening. The demand for stem cells has never been greater. Yet scalable access remains the missing piece. The partnership with Titian Life Sciences provides Cellcolabs with both the capital and strategic footprint needed to grow internationally. Together, we are building the infrastructure that can make stem cell therapies widely available, not someday, but in our lifetime.”
The company was inspired by breakthroughs at Sweden’s renowned Karolinska Institutet. Its mission is to prevent and treat disease by making high-quality stem cells both available and affordable, aiming to take therapies from lab benches straight to the clinic. Over the past 20 years, Cellcolabs has developed a proprietary protocol for manufacturing mesenchymal stem cells (MSCs) in large, GMP-certified batches that fulfil the most rigorous standards for research and patient use.
This approach, the company says, distinguishes Cellcolabs from competitors, including Lonza Group, Thermo Fisher Scientific, and Stemcell Technologies, that still rely on smaller production models and less standardised manufacturing. By building infrastructure tailored to both basic research and clinical therapy, Cellcolabs hopes not only to keep pace with regulatory requirements but also to accelerate scientific advances.
With its new funding, Cellcolabs plans to ramp up research and development, scale up its production capacity, and expand into new international markets.
Kayaan Unwalla, Managing Director of Titian Capital, adds: “The field of regenerative medicine is entering a new era. Our investment in Cellcolabs reflects Titian Capital’s conviction that scalable, standardised production of GMP-grade stem cells will be fundamental to the future of medicine. We are delighted to support Cellcolabs’ expansion and, in doing so, we aim to accelerate the global accessibility of safe, high-quality cellular therapies and help translate cutting-edge science into transformative patient outcomes”
